

certain generally-licensed devices, and specific licensing of all generally-licensed devices currently registered by the NRC.

The NRC believes that the change to compatibility category C will allow Agreement States the flexibility to enhance accountability; retain use of tools to track the location and movement of devices, manufacturers and service providers within the State limit; address issues specific to their jurisdictions; continue programs that have proven beneficial; and to adopt requirements based on their specific circumstances and needs. As directed by the Commission, the NRC staff will assess the degree to which the Agreement States modify their programs as a result of the change in compatibility category and analyze any transboundary impacts to regulated entities, particularly those operating on a multistate basis. If transboundary problems are identified, the staff will suggest any corrective actions that might be necessary (ADAMS Accession No. ML103360262). The Commission also plans to consider proposed updates to the Policy Statement on Adequacy and Compatibility of Agreement State Programs and associated guidance documents to include both safety and source security considerations in the determination process.

#### Closure of the Petition for Rulemaking

In its SRM, the Commission addressed all of the issues raised in the PRM: The Commission disapproved publication of the final rule and approved the change in compatibility for 10 CFR 31.5 and 10 CFR 31.6. The NRC is closing this PRM because all of the petitioners' requests have been resolved.

Dated at Rockville, Maryland, this 22nd day of December 2011.

For the Nuclear Regulatory Commission.

**R.W. Borchardt,**

*Executive Director for Operations.*

[FR Doc. 2012-1523 Filed 1-24-12; 8:45 am]

**BILLING CODE 7590-01-P**

## DEPARTMENT OF COMMERCE

### National Oceanic and Atmospheric Administration

#### 15 CFR Part 922

[Docket No. 100908440-1615-01]

RIN 0648-BA24

#### Proposed Expansion of Fagatele Bay National Marine Sanctuary, Regulatory Changes, and Sanctuary Name Change

**AGENCY:** Office of National Marine Sanctuaries (ONMS), National Ocean Service (NOS), National Oceanic and Atmospheric Administration (NOAA), Department of Commerce (DOC).

**ACTION:** Re-opening of public comment period.

**SUMMARY:** On October 21, 2011, NOAA published a proposed rule in the **Federal Register** to revise the regulations for the Fagatele Bay National Marine Sanctuary (76 FR 65566). This notice re-opens the public comment period stated in that proposed rule until March 9, 2012.

**DATES:** NOAA will accept public comments on the proposed rule published at 76 FR 65566 (October 21, 2011) through March 9, 2012.

**ADDRESSES:** The instructions for submitting comments are detailed in the proposed rule published on October 21, 2011 (76 FR 65566).

**FOR FURTHER INFORMATION CONTACT:** Gene Brighthouse at (684) 633-7792.

Dated: January 17, 2012.

**Daniel J. Basta,**

*Director, Office of National Marine Sanctuaries.*

[FR Doc. 2012-1499 Filed 1-24-12; 8:45 am]

**BILLING CODE 3510-NK-P**

## CONSUMER PRODUCT SAFETY COMMISSION

#### 16 CFR Part 1700

[CPSC Docket No. CPSC-2012-0005]

#### Products Containing Imidazolines Equivalent to 0.08 Milligrams or More

**AGENCY:** Consumer Product Safety Commission.

**ACTION:** Notice of proposed rulemaking.

**SUMMARY:** The Consumer Product Safety Commission ("CPSC," "Commission," or "we") is proposing a rule to require child-resistant ("CR") packaging for any over-the-counter or prescription product containing the equivalent of 0.08 milligrams or more of an imidazoline, a

class of drugs that includes tetrahydrozoline, naphazoline, oxymetazoline, and xylometazoline, in a single package. Imidazolines are a family of drugs that are vasoconstrictors indicated for nasal congestion and/or ophthalmic irritation. Products containing imidazolines can cause serious adverse reactions, such as central nervous system ("CNS") depression, decreased heart rate, and depressed ventilation in children treated with these drugs or who accidentally ingest them. Based on the scientific data, the Commission preliminarily finds that availability of 0.08 milligrams or more of an imidazoline in a single package, by reason of its packaging, is such that special packaging is required to protect children under 5 years old from serious personal injury or illness due to handling, using, or ingesting such a substance. We are taking this action under the Poison Prevention Packaging Act of 1970 ("PPPA").<sup>1</sup>

**DATES:** Written comments must be received by April 9, 2012.

**ADDRESSES:** You may submit comments, identified by Docket No. CPSC-2012-0005, by any of the following methods:

#### Electronic Submissions

Submit electronic comments in the following way:

*Federal eRulemaking Portal:* <http://www.regulations.gov>. Follow the instructions for submitting comments. To ensure timely processing of comments, the Commission is no longer accepting comments submitted by electronic mail (email) except through <http://www.regulations.gov>.

#### Written Submissions

Submit written submissions in the following way:

*Mail/Hand delivery/Courier (for paper, disk, or CD-ROM submissions), preferably in five copies, to:* Office of the Secretary, Consumer Product Safety Commission, Room 802, 4330 East West Highway, Bethesda, MD 20814; telephone (301) 504-7923.

*Instructions:* All submissions received must include the agency name and docket number for this notice of proposed rulemaking. All comments received may be posted without change, including any personal identifiers, contact information, or other personal information provided, to <http://www.regulations.gov>. Do not submit confidential business information, trade

<sup>1</sup> The Commission voted 4-0 to publish this notice in the **Federal Register**. Commissioner Robert S. Adler issued a statement, which can be found at <http://www.cpsc.gov/pr/statements.html>.